FRI0262 CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS WITH POLYMYALGIA SYMPTOMS ONLY VS CRANIAL SYMPTOMS ONLY TREATED WITH TOCILIZUMAB OR PLACEBO IN THE GIACTA TRIAL
Authors: Robert Spiera, Sebastian Unizony, Min Bao, Yves Luder, Paris Sidiropoulos, Jinglan Pei, John H. Stone
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> GiACTA, a randomized, double-blind, placebo (PBO)–controlled study, demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA).<sup>1</sup> Growing evidence has shown that TCZ is also effective for the treatment of polymyalgia rheumatica (PMR); however, data on this are limited.<sup>2,3</sup> <h3>Objectives</h3> To evaluate the efficacy of TCZ in patients with GCA presenting with cranial symptoms only or PMR symptoms only in GiACTA. <h3>Methods</h3> GiACTA randomized 251 GCA patients to receive weekly or every other week TCZ plus a 26-week prednisone taper (TCZ + prednisone) or PBO plus a 26- or 52-week prednisone taper (PBO + prednisone).<sup>1</sup> In this post hoc analysis, baseline characteristics, sustained remission rate, number of flares, annual flare rate, time to flare, cumulative prednisone dose and safety were assessed in patients with PMR symptoms only and patients with cranial symptoms only at diagnosis. Disease flare was defined as the recurrence of signs or symptoms of GCA (including PMR) or an elevation in erythrocyte sedimentation rate attributable to GCA. <h3>Results</h3> Of 146 patients included in the analysis, 52 had PMR symptoms only and 94 had cranial symptoms only at diagnosis. Demographics and other patient characteristics are shown in <b>Table 1</b>. The hazard ratios for flare in patients receiving TCZ vs PBO were 0.77 (99% CI, 0.26-2.32) for patients with PMR symptoms only and 0.37 (99% CI, 0.13-1.01) for patients with cranial symptoms only. Of patients with PMR symptoms only, 18 flares occurred in 13/31 patients (41.9%) in the TCZ group and 20 flares occurred in 12/21 patients (57.1%) in the PBO group. Of patients with cranial symptoms only, 19 flares occurred in 12/58 patients (20.7%) in the TCZ group and 25 flares occurred in 17/36 patients (47.2%) in the PBO group (<b>Table 2</b>). For both the PMR and cranial symptoms only groups, annual flare rates were lower in patients receiving TCZ compared with those receiving PBO. The occurrence of adverse events and serious adverse events was similar between groups (<b>Table 2</b>). <h3>Conclusion</h3> TCZ improved clinical outcomes in patients who presented with PMR symptoms only or cranial symptoms only at diagnosis as indicated by a reduced incidence of flares. These findings suggest that TCZ is effective in patients with GCA with PMR or cranial symptoms. <h3>References</h3> [1] Stone JH, et al. N Engl J Med. 2017;377(4):317-328. [2] Lally L, et al. Arthritis Rheumatol. 2016;68(10):2550-4. [3] Devauchelle-Pensec V, et al. Ann Rheum Dis. 2016;75(8):1506-10. <h3>Disclosure of Interests</h3> Robert Spiera Grant/research support from: Roche-Genentech, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer Ingelheim, Cytori, Chemocentryx, Corbux, Consultant for: Roche-Genentech, GlaxoSmithKline, CSL Behring, Sanofi Aventis, Sebastian Unizony Grant/research support from: F. Hoffmann-La Roche, Genentech, Consultant for: Kiniksa, Sanofi, GSK, Min Bao Shareholder of: F. Hoffmann-La Roche Ltd., Employee of: Genentech, Yves Luder Shareholder of: F. Hoffmann-La Roche, Employee of: F. Hoffmann-La Roche, Paris Sidiropoulos Employee of: Genentech, Jinglan Pei Employee of: Genentech, John H. Stone Grant/research support from: F. Hoffmann-La Roche, Genentech, Xencor, Consultant for: Chugain, F. Hoffmann-La Roche, Genentech, Xencor